115 related articles for article (PubMed ID: 16974115)
1. Expression of Bcl-2 and Ki-67 in tamoxifen-associated endometrial polyps: comparison with postmenopausal polyps.
Altaner S; Gucer F; Tokatli F; Guresci S; Ozdemir C; Puyan FO; Kutlu K
Onkologie; 2006 Sep; 29(8-9):376-80. PubMed ID: 16974115
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor expressions and proliferation markers in postmenopausal endometrial polyps.
Inceboz US; Nese N; Uyar Y; Ozcakir HT; Kurtul O; Baytur YB; Kandiloglu AR; Caglar H; Fraser IS
Gynecol Obstet Invest; 2006; 61(1):24-8. PubMed ID: 16141722
[TBL] [Abstract][Full Text] [Related]
3. Is the immunohistochemical expression of proliferation (Ki-67) and apoptosis (Bcl-2) markers and cyclooxigenase-2 (COX-2) related to carcinogenesis in postmenopausal endometrial polyps?
Antunes A; Andrade LA; Pinto GA; Leão R; Pinto-Neto AM; Costa-Paiva L
Anal Quant Cytopathol Histpathol; 2012 Oct; 34(5):264-72. PubMed ID: 23301386
[TBL] [Abstract][Full Text] [Related]
4. Expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen.
Miranda SP; Traiman P; Cândido EB; Lages EL; Freitas GF; Lamaita RM; Vidigal PV; da Silva Filho AL
Int J Gynecol Cancer; 2010 Dec; 20(9):1525-30. PubMed ID: 21119367
[TBL] [Abstract][Full Text] [Related]
5. Ki-67, Bcl-2 and p53 expression in endometrial polyps and in the normal endometrium during the menstrual cycle.
Maia H; Maltez A; Studart E; Athayde C; Coutinho EM
BJOG; 2004 Nov; 111(11):1242-7. PubMed ID: 15521869
[TBL] [Abstract][Full Text] [Related]
6. Postmenopausal status, hypertension and obesity as risk factors for malignant transformation in endometrial polyps.
Giordano G; Gnetti L; Merisio C; Melpignano M
Maturitas; 2007 Feb; 56(2):190-7. PubMed ID: 16963204
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
8. Expression of the inhibin/activin subunits alpha (alpha), beta-A (betaA) and beta-B (betaB) in benign human endometrial polyps and tamoxifen-associated polyps.
Mylonas I; Makovitzky J; Fernow A; Richter DU; Jeschke U; Briese V; Gerber B; Friese K
Arch Gynecol Obstet; 2005 Jun; 272(1):59-66. PubMed ID: 15309402
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 expression in endometrial polyps during menopause.
Maia H; Correia T; Freitas LA; Athayde C; Coutinho E
Gynecol Endocrinol; 2005 Dec; 21(6):336-9. PubMed ID: 16390782
[TBL] [Abstract][Full Text] [Related]
10. Endometrial pathologies associated with postmenopausal tamoxifen treatment.
Cohen I
Gynecol Oncol; 2004 Aug; 94(2):256-66. PubMed ID: 15297160
[TBL] [Abstract][Full Text] [Related]
11. The differential expression of oestrogen receptors, progesterone receptors, Bcl-2 and Ki67 in endometrial polyps.
Taylor LJ; Jackson TL; Reid JG; Duffy SR
BJOG; 2003 Sep; 110(9):794-8. PubMed ID: 14511960
[TBL] [Abstract][Full Text] [Related]
12. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen.
Lahti E; Blanco G; Kauppila A; Apaja-Sarkkinen M; Taskinen PJ; Laatikainen T
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):660-4. PubMed ID: 8469450
[TBL] [Abstract][Full Text] [Related]
13. Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps? An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to tamoxifen.
McGurgan P; Taylor LJ; Duffy SR; O'Donovan PJ
Maturitas; 2006 Jun; 54(3):252-9. PubMed ID: 16413707
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait.
Al-Azemi M; Labib NS; Motawy MM; Temmim L; Moussa MA; Omu AE
Med Princ Pract; 2004; 13(1):30-4. PubMed ID: 14657616
[TBL] [Abstract][Full Text] [Related]
15. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
[TBL] [Abstract][Full Text] [Related]
16. K-ras mutation in tamoxifen-related endometrial polyps.
Hachisuga T; Miyakawa T; Tsujioka H; Horiuchi S; Emoto M; Kawarabayashi T
Cancer; 2003 Nov; 98(9):1890-7. PubMed ID: 14584071
[TBL] [Abstract][Full Text] [Related]
17. The expression of the hormone receptors in the endometrium and endometrial polyps in postmenopausal women and its relationship to body mass index.
Belisário MS; Vassallo J; Andrade LA; Alvarenga M; Pinto GA; Monteiro IM
Maturitas; 2006 Jan; 53(1):114-8. PubMed ID: 15894442
[TBL] [Abstract][Full Text] [Related]
18. Steroid receptor expression in endometria from women treated with tamoxifen.
Kommoss F; Karck U; Prömpeler H; Pfisterer J; Kirkpatrick CJ
Gynecol Oncol; 1998 Aug; 70(2):188-91. PubMed ID: 9740688
[TBL] [Abstract][Full Text] [Related]
19. Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications.
Risberg B; Karlsson K; Abeler V; Lagrelius A; Davidson B; Karlsson MG
Int J Gynecol Pathol; 2002 Apr; 21(2):155-60. PubMed ID: 11917225
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and the endometrium: review of 102 cases and comparison with HRT-related and non-HRT-related endometrial pathology.
Kennedy MM; Baigrie CF; Manek S
Int J Gynecol Pathol; 1999 Apr; 18(2):130-7. PubMed ID: 10202670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
